Temozolomide 3 weeks on and 1 week off as first-line therapy for recurrent glioblastoma: phase II study from gruppo italiano cooperativo di neuro-oncologia (GICNO). [electronic resource]
Producer: 20061205Description: 1155-60 p. digitalISSN:- 0007-0920
- Adult
- Aged
- Anemia -- chemically induced
- Antineoplastic Agents, Alkylating -- administration & dosage
- Brain Neoplasms -- drug therapy
- Constipation -- chemically induced
- DNA Methylation
- Dacarbazine -- administration & dosage
- Disease Progression
- Drug Administration Schedule
- Female
- Glioblastoma -- drug therapy
- Humans
- Lymphopenia -- chemically induced
- Male
- Middle Aged
- Neoplasm Recurrence, Local
- O(6)-Methylguanine-DNA Methyltransferase -- genetics
- Survival Analysis
- Temozolomide
- Treatment Outcome
No physical items for this record
Publication Type: Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.